Pneumococcal conjugate second or third-dose vaccines (PCVc) in Europe (WHO region)
Europe (WHO region): Pneumococcal conjugate second or third-dose vaccines (PCVc) was 83.0% in 2025. ▲ Rising
Latest (2025)
83.0%
Change on year
unchanged
Rank
3rd
of 11 groups
All-time high
83.0%
in 2023
All-time low
8.0%
in 2008
Years of data
18
2008–2025
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Europe (WHO region), 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
Europe (WHO region) recorded 83.0% for pneumococcal conjugate second or third-dose vaccines (pcvc) in 2025. That is the highest value across all 18 years on record.
That represents a change of up 72.9% over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Europe (WHO region) peaked at 83.0% in 2023 and was at its lowest, 8.0%, in 2008.
The long-run direction has been consistently rising across the 18 years of available data.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Europe (WHO region), year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 8.0% | — |
| 2009 | 23.0% | +187.5% |
| 2010 | 37.0% | +60.9% |
| 2011 | 41.0% | +10.8% |
| 2012 | 43.0% | +4.9% |
| 2013 | 44.0% | +2.3% |
| 2014 | 46.0% | +4.5% |
| 2015 | 48.0% | +4.3% |
| 2016 | 56.0% | +16.7% |
| 2017 | 72.0% | +28.6% |
| 2018 | 77.0% | +6.9% |
| 2019 | 80.0% | +3.9% |
| 2020 | 79.0% | -1.2% |
| 2021 | 81.0% | +2.5% |
| 2022 | 82.0% | +1.2% |
| 2023 | 83.0% | +1.2% |
| 2024 | 83.0% | +0.0% |
| 2025 | 83.0% | +0.0% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 15.5% | 8.0% | 23.0% | 2 |
| 2010s | 54.4% | 37.0% | 80.0% | 10 |
| 2020s | 81.8% | 79.0% | 83.0% | 6 |
Countries ranked near Europe (WHO region)
- 1 Cook Islands 99.0% compare
- 1 Hungary 99.0% compare
- 1 Oman 99.0% compare
- 1 Bahrain 99.0% compare
- 1 Seychelles 99.0% compare
- 1 Bhutan 99.0% compare
- 1 Cuba 99.0% compare
- 1 Palestine, State of 99.0% compare
- 1 Uzbekistan 99.0% compare
- 1 Guyana 99.0% compare
More health data for Europe (WHO region)
- Diphtheria - number of reported cases 199 (2025)
- Pertussis - number of reported cases 52,021 (2025)
- Total tetanus - number of reported cases 85 (2025)
- Measles - number of reported cases 38,686 (2025)
- Neonatal tetanus - number of reported cases 1 (2025)
- Overweight among adults, BMI ≥ 25 kg/m2 (age-standardized estimate) 55.0% (2024)
- Obesity among adults, BMI ≥ 30 kg/m2 (age-standardized estimate) 20.9% (2024)
- Obesity among children and adolescents, BMI-for-age > +2 standard 10.3% (2024)
- Overweight among children and adolescents, BMI-for-age > +1 standard 25.9% (2024)
- Number of infant deaths 63,041 (2024)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Europe (WHO region)?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Europe (WHO region) was 83.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Europe (WHO region)?
- The highest recorded value was 83.0% in 2023.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Europe (WHO region)?
- The lowest recorded value was 8.0% in 2008.
- How does Europe (WHO region) rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Europe (WHO region) ranks 3rd out of 11 groups with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Europe (WHO region)?
- Over the last ten years it is up 72.9%. The long-run trend across the full record is rising.
- Where does this Europe (WHO region) data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).